Acrivon Traders Eye Cancer-Drug News Ahead of the Open
Acrivon Therapeutics shares slipped 2.23% to $1.75 Friday and traded at $1.74 premarket Tuesday ahead of CEO Peter Blume-Jensen’s appearance at TD Cowen’s Oncology Innovation Summit. Investors await interim Phase 2b data on ACR-368 in serous endometrial cancer, expected in the second half of 2026. U.S. markets were closed Monday for Memorial Day.